BioNTech SE’s (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26%
BioNTech SE (NASDAQ:BNTX) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. But the gains over the last month weren’t enough to make shareholders whole, as the share price is still down 4.0% in the last twelve months.
In spite of the firm bounce in price, BioNTech’s price-to-sales (or “P/S”) ratio of 7.9x might still make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 11.9x and even P/S above 77x are quite common. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the reduced P/S.
